FDA
-
-
-
-
-
-
-
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
-
-
-
-
-
-
-
VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
-
-
-
-
-
-
-
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
-
-
-
-
-
-
-
VBL Therapeutics (VBLT) Announces New IND for Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma
-
-
-
-
-
-
-
VBL Therapeutics Receives Milestone Payment From NanoCarrier Under Licensing Agreement for VB-111 in Japan
-
-
-
-
-
-
-
VBL Therapeutics (VBLT) Prices 2.5M Share Offering at $7.5/Sh
-
-
-
-
-
-
-
Pre-Open Movers 11/06: (TXMD) (VBLT) (CAVM) Higher; (S) (TMUS) (VZ) Lower (more...)
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All